See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer regarding a decreased side effect likelihood with lower doses of Cosentyx (secukinumab). The U.S. Food and Drug Administration (FDA) has approved Cosentyx for several indications, and its common side effects include cold symptoms, diarrhea, and upper respiratory infections [1]. However, the FDA does not provide specific information on the side effect likelihood in relation to different doses.

A study published in the Journal of the American Academy of Dermatology investigated the efficacy and safety of different dosing regimens of secukinumab for plaque psoriasis [2]. The study did not find a significant difference in side effects between the different dosing groups. However, this study did not specifically address the question of side effect likelihood in relation to lower doses of Cosentyx.

DrugPatentWatch.com does not provide information on the side effect likelihood of Cosentyx [3]. The website focuses on patent and drug development information.

In conclusion, while there is some information available on the side effects of Cosentyx, there is no definitive evidence to suggest that lower doses of the drug have a decreased side effect likelihood. It is important for individuals to consult with their healthcare provider to determine the appropriate dosage for their specific situation.

Sources:

1. U.S. Food and Drug Administration. Cosentyx (secukinumab) injection, for subcutaneous use. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cosentyx-secukinumab-injection-subcutaneous-use>.
2. Blauvelt, A., de Wit, P. J., Paul, C., Gooderham, M., Thaçi, D., Reich, K., ... & Griffiths, C. E. (2017). Secukinumab provides sustainable improvements in health-related quality of life in moderate-to-severe plaque psoriasis: results from the CLEAR and CLARITY studies. Journal of the American Academy of Dermatology, 76(1), 60-69.
3. DrugPatentWatch.com. Secukinumab. <https://www.drugpatentwatch.com/drugs/secukinumab>.